Effect of TAK‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study

  title={Effect of TAK‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study},
  author={Ichiro Tatsuno and Kentarou Kudou and Tomoya Kagawa},
  journal={Cardiovascular Therapeutics},
  pages={317 - 323}
Summary Background Low‐density lipoproteins (LDLs) comprise a heterogeneous group of particles with various size and density. A shift to larger LDL particle size is mainly the result of a decrease in small dense LDL (sd‐LDL) levels and an increase in large buoyant LDL (lb‐LDL) levels. Methods In a randomized, double‐blind study of TAK‐085 (containing docosahexaenoic and eicosapentaenoic acid‐ethyl esters [EPA‐E]) and an EPA‐E product in Japanese patients with hypertriglyceridemia, exploratory… Expand
N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study
It is suggested that n-3 PUFAs may reduce residual cardiovascular risk factors in statin-treated patients with type 2 diabetes and hypertriglyceridemia and produce less atherogenic lipoprotein subclass ratios. Expand
Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial).
BACKGROUND Numerous studies have demonstrated a reduction in cardiovascular events when the low-density lipoprotein cholesterol (LDL) level is decreased by statin therapy. However, despite goodExpand
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
Icosapent ethyl 4 g/day significantly reduced plasma ApoC-III levels in patients with elevated TGs from the MARINE and ANCHOR studies. Expand
  • Y. Handelsman, M. Shapiro
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2017
There is consistent evidence that triglycerides are in the causal pathway of atherosclerosis but inconsistent evidence from cardiovascular outcomes studies as to whether triglyceride-lowering agents reduce cardiovascular risk. Expand
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients
Omacor® may be a feasible option to treat hypertriglyceridemia in Taiwanese patients and no drug-related serious adverse events were reported during the study. Expand
Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future
ABSTRACT Introduction: Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, andExpand
Keywords: cardiovascular outcomes, eicosapentaenoic acid, fibric acids, niacin, omega-3 fatty acids, triglycerides Abbreviations AACE = American Association of Clinical Endocrinologists; ACCORD = Action to Control Cardiovascular Risk in Diabetes; AIM-HIGH = Atherothrombosis Intervention in Metabolic
© 2016 AACE ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to beExpand


Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.
In Japanese patients with modest hypertriglyceridemia who also underwent lifestyle intervention, TAK-085 4 g/day reduced TG more than EPA-E 1.8 g/ day and was well-tolerated. Expand
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
P-OM3 induces changes in sizes, concentrations, and compositions of lipoproteins that may have relevance for the atherothrombotic process. Expand
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
The view that LDL-P concentration is not increased by POM3 plus atorvastatin, relative to atorVastatin monotherapy, and is associated with potentially favorable shifts in LDL-F subfractions, Apo CIII and lipoprotein-associated phospholipase A(2) in mixed dyslipidemia is supported. Expand
High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia.
It is suggested that high prevalence of small dense LDL in NIDDM patients with nephropathy is not directly associated with kidney damage, and postprandial lipemia may play an important role in reducing LDL particle size in these patients. Expand
Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men.
Cutting atherogenic RLP-C and increased cardio-protective (n-3) index may improve cardio-vascular health and reduce the risk of cardiovascular disease in hypertriglyceridemic men. Expand
Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
P-OM3 + simvastatin appears to be a useful therapeutic option for the management of mixed dyslipidemia. Expand
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men.
EPA and DHA had differential effects on lipids, fatty acids, and glucose metabolism in overweight men with mild hyperlipidemia. Expand
Measurement of small dense low-density lipoprotein particles.
A simple precipitation method is established for the quantification of sd LDL that is applicable to routine clinical use and allows the rapid measurement of a large number of samples. Expand
Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men.
DHA supplementation may improve cardiovascular health by lowering concentrations of triacylglycerols and small, dense LDL particles and the mean diameters of these particles in fasting and postprandial plasma. Expand
Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies
Based on combined data from prospective studies, triglyceride is a risk factor for cardiovascular disease for both men and women in the general population, independent of HDL cholesterol. Expand